A multicenter randomized controlled trial demonstrates notable efficacy outcomes for dual-targeted therapy in EGFR-mutated advanced NSCLC, though several methodological considerations warrant examination.
A recent Nature Medicine study demonstrates that somatic loss of the Y chromosome significantly increases type 2 diabetes risk in East Asian men, particularly those with low polygenic risk scores, with direct evidence of Y chromosome loss in pancreatic β-cells.
A phase I dose-escalation study of rezatapopt demonstrated preliminary antitumor activity in patients with TP53 Y220C-mutated solid tumors, representing the first clinical validation of mutation-specific p53 reactivation therapy.